跳至主要内容
临床试验/ITMCTR1900002841
ITMCTR1900002841招募中未知

The clinical research for Jiedu Qingnao granules additional treatment on first episode schizophrenia according to theory of damage of brain collateral by toxin

Beijing Anding Hospital, Capital Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 40(—)
性别
All

入选标准

  • 1. meet the criteria for the study of first episode schizophrenia;
  • 2. Aged between 18 and 40 years (including 18 and 40);
  • 3. Sign the informed consent and be able to comply with the research scheme;
  • 4. Understand the follow-up questionnaire survey;
  • 5. Meet the criteria of the standard of traditional Chinese medicine syndromes of damage of brain collateral by toxin (hallucinations, delusions, weird thinking, thinking lax, looseness of thought, stunned and speechless, automatic speaking and laughing, solitude, dry mouth, constipation, red tongue, yelow coating of the tongue, pulse string slide).

排除标准

  • 1. Have severe suicidal tendencies;
  • 2. Be in a depressive episode;
  • 3. With serious or unstable heart, liver, kidney, endocrine, blood and other medical diseases;
  • 4. Be treated with antipsychotic medications within 4 weeks;
  • 5. Unattended;
  • 6. Compared to baseline, the reduction rate of PANSS scale screening score is more than 25%.

研究者

相似试验

The clinical research for Jiedu Qingnao granules... | 临床试验